Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: A randomized clinical trial

Journal of Translational Medicine

Volumn 15, Issue 1, 2017, Pages

  Sabico, Shaun ^a,b   Al Mashharawi, Ayah ^b   Al Daghri, Nasser M ^b   Yakout, Sobhy ^b   Alnaami, Abdullah M ^b   Alokail, Majed S ^b   McTernan, Philip G ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Clinical trial; Endotoxin; Lipids; Probiotics; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; ECOLOGIC BARRIER; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROBIOTIC AGENT; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; LIPID;

ABDOMINAL OBESITY; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BACTERIAL STRAIN; BEDTIME DOSAGE; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BLOATING; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INTENTION TO TREAT ANALYSIS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BREVIS; LACTOBACILLUS CASEI; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SAUDI; TREATMENT DURATION; ANTHROPOMETRY; BLOOD; CARDIAC MUSCLE; DIETARY SUPPLEMENT; GLUCOSE BLOOD LEVEL; METABOLISM;

ANTHROPOMETRY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; ENDOTOXINS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIUM; PLACEBOS; PROBIOTICS;

EID: 85037692743     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-017-1354-x     Document Type: Article

References (24)

1. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-20.
2. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, Day CP, McTernan PG. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010;30:7-15.
3. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740-7.
4. Brunkwall L, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia. 2017;60:943-51.
5. Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, Bhutani T, Liao W. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15:73.
6. Alokail MS, Sabico S, Al-Saleh Y, Al-Daghri NM, Alkharfy KM, Vanhoutte PM, McTernan PG. Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2013;14:95.
7. Gomes JM, Costa JA, Alfenas RC. Metabolic endotoxemia and diabetes mellitus: a systemic review. Metabolism. 2017;68:133-44.
8. Brun P, Castigaliuolo I, Leo VD, Buda A, Pinzani M, Palu G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518-25.
9. Le Barz M, Anhe FF, Varin TC, Desjardins Y, Levy E, Roy D, Urdaci MC, Marette A. Probiotics as complementary treatment for metabolic disorders. Diabetes Metab J. 2015;39:291-303.
10. Hu YM, Zhou F, Yuan Y, Xu YC. Effects of probiotics supplement in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Med Clin (Barc). 2017;148:362-70.
11. Gomes AC, de Sousa RG, Botelho PB, Gomes TL, Prada PO, Mota JF. The additional effects of a probiotic mix on abdominal adiposity and antioxidant status. A double-blind, randomized trial. Obesity (Silver Spring). 2017;25:30-8.
12. Karamali M, Dadkhah F, Sadrkhanlou M, Jamilian M, Ahmadi S, Tajabadi-Ebrahimi M, Jafari P, Asemi Z. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab. 2016;42:234-41.
13. Badehnoosh B, Karamali M, Zarrati M, Jamilian M, Bahmani F, Tajabadi-Ebrahimi M, Jafari P, Rahmani E, Asemi Z. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2017. https://doi.org/10.1080/14767058.2017.1310193.
14. Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Cunha JP, Wasserfall C, Casares N, Lasarte JJ, Steidler L, Rottiers P, Dotta F, Gysemans C, Mathieu C. Reversal of diabetes in NOD mice bu clinical-grade pro-insulin and IL-10 secreting Lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells. Diabetes. 2017;66:448-59.
15. Chung PH, Wu YY, Chen PH, Fung CP, Hsu CM, Chen LW. Lactobacillus salivarius reverse diabetes-induced intestinal defense impairment in mice through non-defensin protein. J Nutr Biochem. 2016;35:48-57.
16. Lindsay KL, Brennan L, Kennelly MA, Maguire OC, Smith T, Curran S, Coffey M, Foley ME, Hatunic M, Shanahan F, McAuliffe FM. Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. Am J Obstet Gynecol. 2015;212:496.e1-11.
17. Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr. 2017;56:1535-50.
18. Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35:566-75.
19. Yap WB, Ahmad FM, Lim YC, Zainalabidin S. Lactobacillus casei strain C1 attenuates vascular changes in spontaneously hypertensive rats. Korean J Physiol Pharmacol. 2016;20:621-8.
20. Khalesi S, Sun J, Buys N, Jayasinghe R. Effects of probiotics on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Hypertension. 2014;64:897-903.
21. Luyer MD, Buurman WA, Hadfoune M, Speelmans G, Knowl J, Jacobs JA, Dejong CH, Vriesema AJ, Greve JW. Strain-specific effects of probiotics on gut barrier intergrity following hemorrhagic shock. Infect Immun. 2005;73(6):3686-92.
22. Campana R, van Hemert S, Baffone W. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathog. 2017;9:12.
23. ®Barrier on parameters of intestinal barrier function. Food Nutr Sci. 2014;5:1739-45.
24. Gupta VK, Paul S, Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol. 2017;8:1162.